NASDAQ:HLTH

Cue Health to Announce First Quarter Financial Results

Retrieved on: 
월요일, 4월 29, 2024
Biotechnology, Health Technology, Health, Telemedicine, Virtual Medicine

Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call.

Key Points: 

Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call.

Cue Health Announces Strategic Actions to Position Company for Next Stage

Retrieved on: 
수요일, 3월 20, 2024
Health, Pharmaceutical, Health Technology, Telemedicine, Virtual Medicine, Medical Supplies, Genomics, Medicine, Roche, Khattak, Vaccine, Management

Cue Health Inc. ("Cue" or the “Company”) (Nasdaq: HLTH), a healthcare technology company, today announced strategic actions implemented by its Board of Directors (the “Board”) to best position the Company for its next stage:

Key Points: 
  • Cue Health Inc. ("Cue" or the “Company”) (Nasdaq: HLTH), a healthcare technology company, today announced strategic actions implemented by its Board of Directors (the “Board”) to best position the Company for its next stage:
    Clint Sever, co-founder and current Chief Product Officer, has been appointed CEO, effective immediately.
  • “Cue has an outstanding executive team and we are confident that Clint can seamlessly assume the CEO role, given his deep experience, expertise and familiarity with Cue.
  • We are also pleased to have Paul and Lisa join Cue as strategic advisors, whose experience and insights will be critical to Cue’s next phase.
  • This vision continues to inspire and drive the important work we do every day,” said Clint Sever, CEO of Cue.

Cue Health Reports Fourth Quarter 2023 Financial Results

Retrieved on: 
수요일, 3월 13, 2024
Medical Devices, Infectious Diseases, Health, Health Technology, Telemedicine, Virtual Medicine, Telephone, COVID-19, RSV, GAAP, De novo, FDA, Video game

Cue Health Inc. ("Cue" or the “Company”) (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the fourth quarter and full-year 2023.

Key Points: 
  • Cue Health Inc. ("Cue" or the “Company”) (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the fourth quarter and full-year 2023.
  • “We believe that these successes have positioned us well for 2024.”
    Revenue was $18.8 million for the fourth quarter of 2023.
  • Adjusted operating costs and expenses were $48.3 million in the fourth quarter of 2023, a 49% decrease from $94.6 million in the fourth quarter of 2022.
  • Cue will host a conference call to discuss the fourth quarter and full year 2023 financial results, after market close on Wednesday, March 13, 2024, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Cue Health to Announce Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
수요일, 2월 28, 2024
Biotechnology, Health Technology, Health, Telemedicine, Virtual Medicine, Telephone, Cue

Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024.

Key Points: 
  • Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024.
  • In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • The live webinar of the call may be accessed by visiting the Events section of the Company’s website at investors.cuehealth.com .
  • A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.

Cue Health Announces Appointment of Rishi Reddy to Board of Directors

Retrieved on: 
금요일, 2월 16, 2024
Medical Devices, Health, Health Technology, Other Health, General Health, Biotechnology, Security (finance), Management

Cue Health (Nasdaq: HLTH), a healthcare technology company, today announced it entered into a cooperation agreement (the “Cooperation Agreement”) with Tarsadia Investments (“Tarsadia”), and appointed Rishi Reddy to its board of directors (the “Board”), effective immediately.

Key Points: 
  • Cue Health (Nasdaq: HLTH), a healthcare technology company, today announced it entered into a cooperation agreement (the “Cooperation Agreement”) with Tarsadia Investments (“Tarsadia”), and appointed Rishi Reddy to its board of directors (the “Board”), effective immediately.
  • Mr. Reddy is a Managing Director at Tarsadia, where he leads the firm’s venture and growth equity strategy.
  • He was previously an Observer on Cue’s Board of Directors from April 2018 to September 2021.
  • In addition, the Board intends to commence a process to add an additional highly qualified, independent director to the Board.

Cue Health to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Retrieved on: 
수요일, 1월 31, 2024
Health Technology, Health, Telemedicine, Virtual Medicine, Digital health, Conference

Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13, 2024.

Key Points: 

Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13, 2024.

Cue Health Reports Third Quarter 2023 Financial Results

Retrieved on: 
수요일, 11월 8, 2023
Health, Medical Devices, Telemedicine, Virtual Medicine, FDA, RSV, Herpes simplex, EBITDA, GAAP, PCR, De novo, COVID, COVID-19, Cue, EUA, Cassette tape, Pharmaceutical industry, Payment card, Video game, Bookkeeping, Microbiology Spectrum

Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the third quarter 2023.

Key Points: 
  • Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the third quarter 2023.
  • I’m proud of the Cue team for the strong execution across all fronts.”
    Revenue was $17.5 million for the third quarter of 2023.
  • GAAP net loss in the third quarter of 2023 was $47.0 million and earnings per diluted share was a loss of $0.31, an improvement of $0.24 from the second quarter of 2023.
  • Cue ended the third quarter with cash of $111.5 million and the company continues to operate with no debt obligations.

Cue Health to Announce Third Quarter 2023 Financial Results

Retrieved on: 
수요일, 10월 25, 2023
Health, Telemedicine, Virtual Medicine, Health Technology, Other Health, Managed Care, General Health, Telephone, Cue

Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its third quarter 2023 financial results on Wednesday, November 8, 2023.

Key Points: 
  • Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its third quarter 2023 financial results on Wednesday, November 8, 2023.
  • In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • The live webinar of the call may be accessed by visiting the Events section of the Company’s website at investors.cuehealth.com.
  • A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.

Concerned Stockholders of Cue Health Send Letter to Board

Retrieved on: 
토요일, 10월 7, 2023
Health, General Health, FDA, COVID-19, Concerned, Optimism, Cue, Weather, Stock dilution, Letter, Pharmaceutical industry, Nursing

As you know, I was the founder of Cue Health, Inc. (“Cue Health” or the “Company”) and an investor from the Company’s first seed round, through subsequent rounds of its financing, and together with certain other stockholders of the Company (the “Concerned Stockholders”), own approximately 7.5% of Cue Health’s outstanding stock.

Key Points: 
  • As you know, I was the founder of Cue Health, Inc. (“Cue Health” or the “Company”) and an investor from the Company’s first seed round, through subsequent rounds of its financing, and together with certain other stockholders of the Company (the “Concerned Stockholders”), own approximately 7.5% of Cue Health’s outstanding stock.
  • Since its founding in 2010, Cue Health has developed game-changing diagnostics to enable lab-quality care at home, work or at the point of care.
  • The Concerned Stockholders believe that the Board must take immediate action to stabilize the Company, substantially reduce its cash burn, and focus on its core diagnostic business.
  • The Concerned Stockholders urge the Board to heed our voices as long-term stockholders and take action today.

Peer-Reviewed Independent Study Published in Microbiology Spectrum Finds Cue Health’s Molecular COVID-19 Test is as Accurate as a Lab-Based PCR Test

Retrieved on: 
수요일, 10월 4, 2023
Biotechnology, Health, COVID-19, Clinical Trials, Infection, Microbiology, De novo, RNS, Landing slot, ISO, American Society for Microbiology, RT-PCR, FH, COVID-19 testing, Trial of the century, Viral load, Immunodeficiency, FDA, RT, Health Canada, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Cue, PCR, Food, Pharmaceutical industry, Nursing, Vaccine, Microbiology Spectrum

The study, published in Microbiology Spectrum, a journal produced by the American Society for Microbiology, presents findings from a head-to-head comparison of the Cue COVID-19 test against lab-based RT-PCR on paired samples from 3,037 individuals.

Key Points: 
  • The study, published in Microbiology Spectrum, a journal produced by the American Society for Microbiology, presents findings from a head-to-head comparison of the Cue COVID-19 test against lab-based RT-PCR on paired samples from 3,037 individuals.
  • The findings from paired testing revealed a 99.4% match between results from Cue’s test and the reference PCR tests with 100% clinical sensitivity to detect positive cases, yielding no false negatives.
  • To further expand its diagnostic test menu for at-home and point-of-care use, Cue has made a number of other submissions with the FDA.
  • Cue did not provide funding or any other support of the study.